众生药业
(002317)
| 流通市值：96.34亿 | | | 总市值：107.72亿 |
| 流通股本：7.62亿 | | | 总股本：8.52亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 634,261,440.11 | 2,467,418,394.64 | 1,908,022,039.84 | 1,364,366,722.8 |
| 营业收入 | 634,261,440.11 | 2,467,418,394.64 | 1,908,022,039.84 | 1,364,366,722.8 |
| 利息收入 | 0 | 0 | 0 | 0 |
| 已赚保费 | 0 | 0 | 0 | 0 |
| 手续费及佣金收入 | 0 | 0 | 0 | 0 |
| 二、营业总成本 | 546,759,207.07 | 2,228,489,469.54 | 1,701,672,490.4 | 1,174,830,188.15 |
| 营业成本 | 275,368,528.16 | 1,084,821,829.52 | 837,942,033.19 | 587,700,660.15 |
| 利息支出 | 0 | 0 | 0 | 0 |
| 手续费及佣金支出 | 0 | 0 | 0 | 0 |
| 退保金 | 0 | 0 | 0 | 0 |
| 赔付支出净额 | 0 | 0 | 0 | 0 |
| 提取保险合同准备金净额 | 0 | 0 | 0 | 0 |
| 保单红利支出 | 0 | 0 | 0 | 0 |
| 分保费用 | 0 | 0 | 0 | 0 |
| 税金及附加 | 6,347,330.99 | 21,454,071.28 | 17,097,576.55 | 13,588,445.51 |
| 销售费用 | 218,567,447.02 | 850,433,612.18 | 645,880,775.21 | 442,514,542.78 |
| 管理费用 | 30,575,841.15 | 151,749,299.47 | 108,472,335.72 | 69,542,088.11 |
| 研发费用 | 15,923,565.59 | 111,203,585.62 | 86,091,412.48 | 57,459,831.33 |
| 财务费用 | -23,505.84 | 8,827,071.47 | 6,188,357.25 | 4,024,620.27 |
| 其中:利息费用 | 3,046,387.16 | 25,345,328.45 | 23,244,729.18 | 16,124,838.53 |
| 其中:利息收入 | 2,932,282.83 | 18,767,667.78 | 16,279,711.69 | 12,875,010.48 |
| 加:公允价值变动收益 | 966,814.44 | -18,219,305.06 | 5,861,092.4 | -47,816,614.28 |
| 加:投资收益 | 4,179,582.72 | 24,869,018.33 | 20,840,773.22 | 15,260,783.66 |
| 净敞口套期收益 | 0 | 0 | 0 | 0 |
| 汇兑收益 | 0 | 0 | 0 | 0 |
| 资产处置收益 | -4,745.46 | 28,462.2 | 28,175.01 | 28,175.01 |
| 资产减值损失(新) | 0 | -546,680,714.81 | -919,357.81 | -919,357.81 |
| 信用减值损失(新) | -2,417,375.49 | -5,662,803.76 | -6,935,540.55 | -5,448,897.53 |
| 其他收益 | 9,079,567.1 | 26,784,475.09 | 11,105,582.16 | 6,927,841.9 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 99,306,076.35 | -279,951,942.91 | 236,330,273.87 | 157,568,465.6 |
| 加:营业外收入 | 10,577.97 | 173,047.24 | 89,504.82 | 62,513.97 |
| 减:营业外支出 | 54,383.25 | 56,102,790.83 | 58,696,945.18 | 58,023,326.18 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 99,262,271.07 | -335,881,686.5 | 177,722,833.51 | 99,607,653.39 |
| 减:所得税费用 | 17,814,054.06 | 38,081,795.6 | 41,811,969.92 | 20,773,362.87 |
| 六、净利润 | 81,448,217.01 | -373,963,482.1 | 135,910,863.59 | 78,834,290.52 |
| 持续经营净利润 | 81,448,217.01 | -373,963,482.1 | 135,910,863.59 | 78,834,290.52 |
| 终止经营净利润 | 0 | 0 | 0 | 0 |
| 归属于母公司股东的净利润 | 82,611,839.1 | -299,157,116.72 | 148,802,427.39 | 87,409,781.47 |
| 少数股东损益 | -1,163,622.09 | -74,806,365.38 | -12,891,563.8 | -8,575,490.95 |
| (一)基本每股收益 | 0.1 | -0.36 | 0.18 | 0.1 |
| (二)稀释每股收益 | 0.1 | -0.36 | 0.18 | 0.1 |
| 八、其他综合收益 | -2,834,799.65 | -2,507,517.14 | -448,465.64 | -145,671.64 |
| 归属于母公司股东的其他综合收益 | -2,834,799.65 | -2,507,517.14 | -448,465.64 | -145,671.64 |
| 九、综合收益总额 | 78,613,417.36 | -376,470,999.24 | 135,462,397.95 | 78,688,618.88 |
| 归属于母公司股东的综合收益总额 | 79,777,039.45 | -301,664,633.86 | 148,353,961.75 | 87,264,109.83 |
| 归属于少数股东的综合收益总额 | -1,163,622.09 | -74,806,365.38 | -12,891,563.8 | -8,575,490.95 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-29 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |